Bluebird bio Inc
NASDAQ:BLUE 12:25:55 AM EDT
| Market Cap (Intraday) | 99.32M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.57 |
| 50-Day MA | $0.88 |
| 200-Day MA | $1.25 |
Bluebird bio Inc Stock, NASDAQ:BLUE
60 Binney Street, 455 Grand Union Boulevard, Somerville, Massachusetts 02145
United States of America
Phone: +1.339.499.9300
Number of Employees: 375
Description
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.